All In Biotech

Drug Trial Radar · NCT06173778

Semaglutide for Post-Smoking Cessation Weight Management

A Randomized Controlled Trial of Once-Weekly Semaglutide for Limiting Post-Smoking Cessation Weight Gain in Adult Smokers With Overweight/Obesity

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 197 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

197

Planned (sponsor's estimate)

Start

Apr 23, 2024

Primary completion

May 25, 2028

Study completion Jun 25, 2028

Sponsor

Lead sponsor
The University of Texas Health Science Center, HoustonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

Conditions

  • Obesity
  • Overweight
  • Cigarette Smoking

Interventions

  • semaglutide 2.4mgDrug

    Semaglutide 2.4mg will be self-administered once a week under the surface of the skin and will be started at 0.24mg or 0.25mg once a week for 4 weeks; in 4-week intervals, the dose will be increased until a dose of 2.4mg is reached

  • PlaceboDrug

    Non-active medication, self-administered

  • Nicotine Replacement Therapy (NRT, nicotine patch)Drug

    Participants who smoke \>10 cigarettes/day will use 21 mg patches for the first 6 weeks, 14 mg patches during weeks 7 and 8, and 7 mg patches during weeks 9 and 10. Participants who smoke 5-10 cigarettes per day will use 14 mg patches for the first 6 weeks and 7 mg patches for weeks 7-10.

  • Brief Smoking Cessation CounselingBehavioral

    Participants will receive weekly, manual-based individual smoking cessation counseling. Counseling will be provided by master's level clinicians.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Body Weight PercentTime frame: Baseline to Week 28

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Texas at Austin

    Austin, Texas · Recruiting

  • The University of Texas Health Science Center at Houston

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.